Given the high turnover of NAD in cancer cells and the fact that NAMPT is the rate-limiting enzyme in the salvage pathway, inhibitors of NAMPT were first reported as possible anticancer agents by Hasmann et al. This evidence concerns the gene NAMPT and cancer.